GlassScriptPhysician profile
Oscar Molina
NPI 1174015051
$1,097.27
in general payments reported to CMS, 2019-2025
26 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $97.97 · 2024: $702 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $166.80 | 2024 | |
| Pfizer INC. | $94.11 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $93.24 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $88.03 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $80.35 | 2024 | Repatha, Otezla |
| Organogenesis INC. | $73.10 | 2024-2025 | Apligraf, Affinity |
| Exact Sciences Corporation | $43.80 | 2023-2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $42.47 | 2025 | Inspire |
| Novo Nordisk INC | $39.69 | 2025 | Ozempic, Wegovy |
| Lundbeck LLC | $39.06 | 2023-2024 | Rexulti |
| Kerecis Limited | $36.89 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Mimedx Group, INC. | $33.02 | 2024 | |
| Glaxosmithkline, LLC. | $28.15 | 2023 | Arexvy, Shingrix |
| Medtronic, INC. | $26.97 | 2025 | Intellis Adaptivestim |
| Abbvie INC. | $24.17 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Solventum Corporation | $23.98 | 2024 | V.A.C. Granufoam, Activ.A.C. |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.32 | 2025 | |
| Sumitomo Pharma America, INC. | $21.79 | 2024 | Gemtesa |
| Abbott Laboratories | $18.91 | 2024 | Freestyle Libre 3 |
| Hydrofera LLC | $17.66 | 2024 | Hydrofera Blue |
| Axsome Therapeutics, INC. | $16.52 | 2024 | Auvelity |
| Hartmann USA, INC. | $15.73 | 2025 | Zetuvit Plus 10x10 P10 |
| Smith+Nephew, INC. | $15.35 | 2025 | Collagenase Santyl, Regranex |
| Convatec INC. | $15.22 | 2024 | |
| Spinal Simplicity, LLC | $13.82 | 2025 | Ha Minuteman G3-R |
| Cashflow Solutions, LLC | $6.12 | 2024 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Molina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.